Collectively, these data demonstrate that while PDTC treatment attenuated body weight and muscle mass loss, systemic inflammation related to plasma IL-6 and total tumor number remained elevated regardless of PDTC treatment in ApcMin/+ mice. The gene discussed is IL6; the disease is neoplasm.